{"protocolSection": {"identificationModule": {"nctId": "NCT02230891", "orgStudyIdInfo": {"id": "CLNB-009-13F"}, "organization": {"fullName": "VA Office of Research and Development", "class": "FED"}, "briefTitle": "Biomarker Guided Therapies in Stage A/B Heart Failure", "officialTitle": "Biomarker Guided Therapies in Stage A/B Heart Failure"}, "statusModule": {"statusVerifiedDate": "2022-10", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2014-10-01", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2020-12-15", "type": "ACTUAL"}, "completionDateStruct": {"date": "2020-12-15", "type": "ACTUAL"}, "studyFirstSubmitDate": "2014-08-28", "studyFirstSubmitQcDate": "2014-08-28", "studyFirstPostDateStruct": {"date": "2014-09-03", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2022-06-30", "resultsFirstSubmitQcDate": "2022-09-01", "resultsFirstPostDateStruct": {"date": "2022-09-29", "type": "ACTUAL"}, "dispFirstSubmitDate": "2021-12-10", "dispFirstSubmitQcDate": "2021-12-10", "dispFirstPostDateStruct": {"date": "2021-12-15", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2022-10-19", "lastUpdatePostDateStruct": {"date": "2022-10-21", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "VA Office of Research and Development", "class": "FED"}, "collaborators": [{"name": "Baylor College of Medicine", "class": "OTHER"}]}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false, "isUsExport": false}, "descriptionModule": {"briefSummary": "Despite advances in cardiovascular care, the occurrence of heart failure (HF) is steadily increasing. The increase in HF rates poses enormous challenges, as once an individual becomes symptomatic or requires hospitalization with HF, the prognosis remains poor. Therefore, prevention of HF is essential. HF prevention is a critical issue as HF risk factors that include common medical conditions such as hypertension and diabetes are also increasing. However, not everyone with these risk factors develops HF. Using novel blood tests, the investigators propose to identify and treat subjects at higher HF risk to see if the investigators can stabilize or improve ultrasound measures known to be associated with HF risk. This study will enroll only Veterans.", "detailedDescription": "Recently the investigators have shown that HF risk prediction can be improved using cardiac troponin T measured with a novel high-sensitivity assay (hs-cTnT) and N-terminal pro-B-type natriuretic peptide (NT-proBNP). Furthermore, hs-cTnT seems to identify individuals at higher risk among those with established risk factors (such as hypertension) for HF. In preliminary results, the investigators have shown that individuals with systolic blood pressure of 120-129 mm Hg and elevated hs-cTnT have a higher rate of incident HF than those with systolic blood pressure of 140-159 mm Hg and undetectable hs-cTnT. Therefore, the investigators believe that by using hs-cTnT to estimate HF risk the investigators can identify individuals in whom aggressive modification of risk factors such as high blood pressure will be associated with a favorable risk-benefit ratio.\n\nThe investigators' objective/specific aim therefore is to evaluate if treatment of selected subjects with Stage A or B HF (i.e., those with hs-cTnT \\>5 ng/L and an estimated 10-year HF hospitalization risk of \\>5%) who have reasonably well-controlled blood pressure with antihypertensive agents (carvedilol or spironolactone) will be associated with improvement of surrogate markers associated with incident HF (i.e., speckle-tracked cardiac and vascular strain). Carvedilol and spironolactone were chosen for the following reasons: a) they are not routinely used as first-line antihypertensive agents; b) beta-blockade was associated with decreases in hs-cTnT in the preliminary analysis of subjects with established HF; and c) the mechanism of actions of carvedilol and spironolactone provide a sound scientific rationale for use in prevention of HF.\n\nUsing a prospective open-label blinded end point (PROBE) design, the investigators propose to randomize 210 subjects aged \\>40 years with systolic blood pressure between 120-155 mm Hg, cardiac troponin T (measured with a novel high-sensitivity assay) level \\>5 ng/L, and 10-year HF risk \\>5% (estimated using a validated laboratory model including demographic factors, NT-proBNP, and hs-cTnT) to receive carvedilol (nonselective beta-blocker), spironolactone (aldosterone antagonist), or usual care for 18 months. The primary end point will be change in global longitudinal systolic myocardial strain estimated using 2D speckle tracking. Additionally, changes in vascular strain and biomarkers will be evaluated. This study will help us identify whether both or either of the medications can be further tested in large randomized clinical trials to prevent the incidence of HF."}, "conditionsModule": {"conditions": ["Hypertension", "Diabetes", "Cardiovascular Disease"], "keywords": ["heart failure", "biomarkers", "troponin", "BNP", "carvedilol", "spironolactone", "prevention"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "PREVENTION", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 58, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Carvedilol", "type": "ACTIVE_COMPARATOR", "description": "Approximately 70 subjects will be randomized to carvedilol", "interventionNames": ["Drug: Carvedilol"]}, {"label": "Spironolactone", "type": "ACTIVE_COMPARATOR", "description": "Approximately 70 subjects will be randomized to spironolactone", "interventionNames": ["Drug: Spironolactone"]}, {"label": "Usual care", "type": "OTHER", "description": "Approximately 70 subjects will be randomized to usual care/ standard care by primary care providers", "interventionNames": ["Other: Usual care"]}], "interventions": [{"type": "DRUG", "name": "Carvedilol", "description": "Carvedilol is a non selective beta blocker", "armGroupLabels": ["Carvedilol"]}, {"type": "DRUG", "name": "Spironolactone", "description": "Spironolactone is an aldosterone antagonist and can lower blood pressure/ is used in heart failure", "armGroupLabels": ["Spironolactone"]}, {"type": "OTHER", "name": "Usual care", "description": "standard care as per primary care provider", "armGroupLabels": ["Usual care"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in Cardiac Global Longitudinal Strain", "description": "Change in myocardial speckle tracked strain (global longitudinal strain) after 18 months (baseline vs. 18 months) of therapy with carvedilol or spironolactone or usual care. The myocardial global longitudinal strain was measured using echocardiography", "timeFrame": "18 months"}], "secondaryOutcomes": [{"measure": "Change in NTproBNP (Biomarker)", "description": "Change in levels of NT-proBNP (measured in blood samples) between baseline and 18 months after therapy with carvedilol or spironolactone or usual care", "timeFrame": "18 months"}, {"measure": "Change in Pulse Wave Velocity", "description": "Changes in arterial stiffness between baseline and 18 months after therapy with carvedilol, spironolactone or usual care. Arterial stiffness was measured by pulse wave velocity (Sphygmocor device)", "timeFrame": "18 months"}, {"measure": "Change in Troponin T Measured Using a High Sensitivity Assay", "description": "Change in levels of troponin T (measured with a high sensitivity assay in blood samples) between baseline and 18 months after therapy with carvedilol or spironolactone or usual care", "timeFrame": "18 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\nOnly Veterans are eligible to participate. Other inclusion criteria include\n\n* Age greater than 40 years\n* One of the following in order to establish Stage A HF a. Hypertension b. Diabetes mellitus (controlled: defined as hemoglobin A1c less than 9%) c. Obesity (defined as BMI greater than 30 kg/m2) d. Metabolic syndrome (using the National Cholesterol Education Panel definition) e. Left ventricular hypertrophy (by ECG) f. Coronary or cerebrovascular arterial disease\n* Troponin T measured by the high sensitivity assay of greater than 5ng/L\n* Systolic BP 120-155 mmHg at primary care provider (PCP) visit and prerandomization visit (i.e., 2 separate confirmations of the same). If there is discordance between the PCP visit and pre-randomization the investigators will bring patient back to recheck his BP and use that as the tie breaker. Not orthostatic with measurements (defined as a fall in systolic BP greater than 20 mmHg when subjects assume an upright position). - Estimated 10-yr HF risk (based on Atherosclerosis Risk in Communities HF Lab model) greater than 5%\n* Provides informed consent\n\nExclusion Criteria:\n\nThe exclusion criteria include\n\n* Active Atrial fibrillation\n* History of chest/ neck radiation\n* High-risk chronic obstructive pulmonary disease (COPD) (GOLD classification 3-4 with greater than equal to 2 COPD exacerbations in the last 12 months)\n* Known allergy to carvedilol or spironolactone\n* Renal insufficiency with estimated Glomerular Filtration Rate (eGFR) less than 60 ml/min\n* Serum potassium greater than 5 meq/L\n* Current use of carvedilol, spironolactone, any other beta-blockers or aldosterone antagonists\n* Signs of clinical HF on initial examination (pulmonary rales/crackles, elevated jugular venous pulse with S3/S4 on auscultation)\n* Left ventricular ejection fraction \\<50% by echo\n* Moderate or greater valve stenosis or regurgitation\n* Hypertrophic cardiomyopathy\n* Exposure to known cardiotoxic chemotherapy\n* Poor echo image quality\n* Right ventricular dysfunction more than mild\n* Any valvular dysfunction that is more than mild\n* Any life-threatening disease expected to result in death within the next 2 years\n* Active severe liver disease (evaluated at Visit 1): cirrhosis, active hepatitis, aspartate transaminase (ALT) or alanine transaminase (AST) greater than 3 x ULN, or biliary obstruction with hyperbilirubinemia (total bilirubin greater than 2 x ULN).\n* Participation in another clinical trial involving an investigational agent within 90 days prior to randomization\n* Any condition or therapy which, in the opinion of the investigator, might pose a risk to the patient or make participation in the study not in the patient s best interest\n* Drug or alcohol abuse within the past 6 months, and unable/unwilling to abstain from drug abuse and excessive alcohol consumption during the study. Excessive alcohol consumption is on average greater than 2 units of alcohol per day. A unit of alcohol is defined as a 12-ounce (350 mL) beer, 5-ounce (150 mL) wine, or 1.5-ounce (45 mL) of 80 \\]proof alcohol for drinks.\n* Mental/psychological impairment or any other reason to expect patient difficulty in complying with the requirements of the study.\n* Any immunosuppressed condition where intercurrent illnesses may affect interpretation of study results\n* Pregnant women or any woman planning a pregnancy during the study period\n* Not meeting any of the inclusion criteria", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "40 Years", "maximumAge": "85 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Vijay Nambi, MBBS", "affiliation": "Michael E. DeBakey VA Medical Center, Houston, TX", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Michael E. DeBakey VA Medical Center, Houston, TX", "city": "Houston", "state": "Texas", "zip": "77030", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Carvedilol", "description": "Approximately 70 subjects will be randomized to carvedilol\n\nCarvedilol: Carvedilol is a non selective beta blocker. Dose will be 3.125 mg two times daily with increases in dose if blood pressure permits"}, {"id": "FG001", "title": "Spironolactone", "description": "Approximately 70 subjects will be randomized to spironolactone\n\nSpironolactone: Spironolactone is an aldosterone antagonist and can lower blood pressure/ is used in heart failure. Spironolactone dose will be 25 mg by mouth once daily"}, {"id": "FG002", "title": "Usual Care", "description": "Approximately 70 subjects will be randomized to usual care/ standard care by primary care providers\n\nUsual care: standard care as per primary care provider"}], "periods": [{"title": "Baseline", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "21"}, {"groupId": "FG001", "numSubjects": "18"}, {"groupId": "FG002", "numSubjects": "19"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "21"}, {"groupId": "FG001", "numSubjects": "17"}, {"groupId": "FG002", "numSubjects": "18"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Did not meet inclusion", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}]}]}, {"title": "2 Week", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "21"}, {"groupId": "FG001", "numSubjects": "17"}, {"groupId": "FG002", "comment": "No week 2 for subjects in usual care", "numSubjects": "0"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "18"}, {"groupId": "FG001", "numSubjects": "15"}, {"groupId": "FG002", "comment": "No week 2 for subjects in usual care", "numSubjects": "0"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Consent withdrawn", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}]}, {"title": "6 Month", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "18"}, {"groupId": "FG001", "numSubjects": "15"}, {"groupId": "FG002", "numSubjects": "18"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "17"}, {"groupId": "FG001", "numSubjects": "12"}, {"groupId": "FG002", "numSubjects": "17"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "0"}]}]}, {"title": "12 Month", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "17"}, {"groupId": "FG001", "numSubjects": "12"}, {"groupId": "FG002", "numSubjects": "17"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "9"}, {"groupId": "FG002", "numSubjects": "17"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "0"}]}]}, {"title": "18 Month End of Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "9"}, {"groupId": "FG002", "numSubjects": "17"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "15"}, {"groupId": "FG001", "numSubjects": "9"}, {"groupId": "FG002", "numSubjects": "16"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Hear failure, lost to follow up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "These include individuals who participated in the study. Patient who withdrew consent and one who did not meet eligibility criteria and hence was excluded not included", "groups": [{"id": "BG000", "title": "Carvedilol", "description": "Approximately 70 subjects will be randomized to carvedilol\n\nCarvedilol: Carvedilol is a non selective beta blocker"}, {"id": "BG001", "title": "Spironolactone", "description": "Approximately 70 subjects will be randomized to spironolactone\n\nSpironolactone: Spironolactone is an aldosterone antagonist and can lower blood pressure/ is used in heart failure"}, {"id": "BG002", "title": "Usual Care", "description": "Approximately 70 subjects will be randomized to usual care/ standard care by primary care providers\n\nUsual care: standard care as per primary care provider"}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "20"}, {"groupId": "BG001", "value": "18"}, {"groupId": "BG002", "value": "18"}, {"groupId": "BG003", "value": "56"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "20"}, {"groupId": "BG001", "value": "18"}, {"groupId": "BG002", "value": "18"}, {"groupId": "BG003", "value": "56"}]}], "categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "8"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "19"}, {"groupId": "BG001", "value": "14"}, {"groupId": "BG002", "value": "15"}, {"groupId": "BG003", "value": "48"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "20"}, {"groupId": "BG001", "value": "18"}, {"groupId": "BG002", "value": "18"}, {"groupId": "BG003", "value": "56"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "70.6", "spread": "5.3"}, {"groupId": "BG001", "value": "69.2", "spread": "6.5"}, {"groupId": "BG002", "value": "70.6", "spread": "5.8"}, {"groupId": "BG003", "value": "70.1", "spread": "5.8"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "20"}, {"groupId": "BG001", "value": "18"}, {"groupId": "BG002", "value": "18"}, {"groupId": "BG003", "value": "56"}]}], "categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "20"}, {"groupId": "BG001", "value": "18"}, {"groupId": "BG002", "value": "18"}, {"groupId": "BG003", "value": "56"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "20"}, {"groupId": "BG001", "value": "18"}, {"groupId": "BG002", "value": "18"}, {"groupId": "BG003", "value": "56"}]}], "categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "26"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "13"}, {"groupId": "BG003", "value": "30"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "20"}, {"groupId": "BG001", "value": "18"}, {"groupId": "BG002", "value": "18"}, {"groupId": "BG003", "value": "56"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "20"}, {"groupId": "BG001", "value": "18"}, {"groupId": "BG002", "value": "18"}, {"groupId": "BG003", "value": "58"}]}]}]}, {"title": "Baseline troponin", "populationDescription": "One subject baseline biomarker not available", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "ng/L", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "19"}, {"groupId": "BG001", "value": "18"}, {"groupId": "BG002", "value": "18"}, {"groupId": "BG003", "value": "55"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "14.6", "spread": "3.3"}, {"groupId": "BG001", "value": "15.4", "spread": "4.6"}, {"groupId": "BG002", "value": "17.1", "spread": "4.4"}, {"groupId": "BG003", "value": "15.7", "spread": "4.2"}]}]}]}, {"title": "N-terminal (NT)-pro hormone BNP (NT-proBNP)", "populationDescription": "One subject baseline biomarker not available", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "pg/ml", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "19"}, {"groupId": "BG001", "value": "18"}, {"groupId": "BG002", "value": "18"}, {"groupId": "BG003", "value": "55"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "97.0", "spread": "78.7"}, {"groupId": "BG001", "value": "72.2", "spread": "73.5"}, {"groupId": "BG002", "value": "96.6", "spread": "76.4"}, {"groupId": "BG003", "value": "88.7", "spread": "75.7"}]}]}]}, {"title": "Pulse wave velocity (PWV)", "populationDescription": "Based on available data for analysis", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "m/sec", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "14"}, {"groupId": "BG001", "value": "14"}, {"groupId": "BG002", "value": "13"}, {"groupId": "BG003", "value": "41"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "10.6", "spread": "4.9"}, {"groupId": "BG001", "value": "9.4", "spread": "5.5"}, {"groupId": "BG002", "value": "8.5", "spread": "4.1"}, {"groupId": "BG003", "value": "9.5", "spread": "4.8"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in Cardiac Global Longitudinal Strain", "description": "Change in myocardial speckle tracked strain (global longitudinal strain) after 18 months (baseline vs. 18 months) of therapy with carvedilol or spironolactone or usual care. The myocardial global longitudinal strain was measured using echocardiography", "populationDescription": "Difference is global longitudinal strain between baseline and 18 months for those who completed both visits and had data available", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "% systolic deformation", "timeFrame": "18 months", "groups": [{"id": "OG000", "title": "Carvedilol", "description": "Approximately 70 subjects will be randomized to carvedilol\n\nCarvedilol: Carvedilol is a non selective beta blocker"}, {"id": "OG001", "title": "Spironolactone", "description": "Approximately 70 subjects will be randomized to spironolactone\n\nSpironolactone: Spironolactone is an aldosterone antagonist and can lower blood pressure/ is used in heart failure"}, {"id": "OG002", "title": "Usual Care", "description": "Approximately 70 subjects will be randomized to usual care/ standard care by primary care providers\n\nUsual care: standard care as per primary care provider"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "9"}, {"groupId": "OG002", "value": "13"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.4", "spread": "4.4"}, {"groupId": "OG001", "value": "-1.74", "spread": "3.25"}, {"groupId": "OG002", "value": "-1.14", "spread": "4.13"}]}]}]}, {"type": "SECONDARY", "title": "Change in NTproBNP (Biomarker)", "description": "Change in levels of NT-proBNP (measured in blood samples) between baseline and 18 months after therapy with carvedilol or spironolactone or usual care", "populationDescription": "Those who completed study and had data available", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pg/ml", "timeFrame": "18 months", "groups": [{"id": "OG000", "title": "Carvedilol", "description": "Approximately 70 subjects will be randomized to carvedilol\n\nCarvedilol: Carvedilol is a non selective beta blocker"}, {"id": "OG001", "title": "Spironolactone", "description": "Approximately 70 subjects will be randomized to spironolactone\n\nSpironolactone: Spironolactone is an aldosterone antagonist and can lower blood pressure/ is used in heart failure"}, {"id": "OG002", "title": "Usual Care", "description": "Approximately 70 subjects will be randomized to usual care/ standard care by primary care providers\n\nUsual care: standard care as per primary care provider"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "87.9", "spread": "243.5"}, {"groupId": "OG001", "value": "-16.5", "spread": "39.3"}, {"groupId": "OG002", "value": "3.65", "spread": "91.03"}]}]}]}, {"type": "SECONDARY", "title": "Change in Pulse Wave Velocity", "description": "Changes in arterial stiffness between baseline and 18 months after therapy with carvedilol, spironolactone or usual care. Arterial stiffness was measured by pulse wave velocity (Sphygmocor device)", "populationDescription": "Based on available measures at baseline and end of study. Reported values are change in Pulse wave velocity (PWV) between visits", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "m/sec", "timeFrame": "18 months", "groups": [{"id": "OG000", "title": "Carvedilol", "description": "Approximately 70 subjects will be randomized to carvedilol\n\nCarvedilol: Carvedilol is a non selective beta blocker"}, {"id": "OG001", "title": "Spironolactone", "description": "Approximately 70 subjects will be randomized to spironolactone\n\nSpironolactone: Spironolactone is an aldosterone antagonist and can lower blood pressure/ is used in heart failure"}, {"id": "OG002", "title": "Usual Care", "description": "Approximately 70 subjects will be randomized to usual care/ standard care by primary care providers\n\nUsual care: standard care as per primary care provider"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "11"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.71", "spread": "1.6"}, {"groupId": "OG001", "value": "-0.77", "spread": "5.7"}, {"groupId": "OG002", "value": "-0.59", "spread": "3.4"}]}]}]}, {"type": "SECONDARY", "title": "Change in Troponin T Measured Using a High Sensitivity Assay", "description": "Change in levels of troponin T (measured with a high sensitivity assay in blood samples) between baseline and 18 months after therapy with carvedilol or spironolactone or usual care", "populationDescription": "Those who completed study and had data available", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/L", "timeFrame": "18 months", "groups": [{"id": "OG000", "title": "Carvedilol", "description": "Approximately 70 subjects will be randomized to carvedilol\n\nCarvedilol: Carvedilol is a non selective beta blocker. Dose will be 3.125 mg two times daily with increases in dose if blood pressure permits"}, {"id": "OG001", "title": "Spironolactone", "description": "Approximately 70 subjects will be randomized to spironolactone\n\nSpironolactone: Spironolactone is an aldosterone antagonist and can lower blood pressure/ is used in heart failure. Spironolactone dose will be 25 mg by mouth once daily"}, {"id": "OG002", "title": "Usual Care", "description": "Approximately 70 subjects will be randomized to usual care/ standard care by primary care providers\n\nUsual care: standard care as per primary care provider"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.2", "spread": "5.2"}, {"groupId": "OG001", "value": "1.4", "spread": "3.9"}, {"groupId": "OG002", "value": "0.35", "spread": "6.0"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "1", "timeFrame": "The study had a follow up period of 18 months from randomization during which subjects were followed for adverse events. However, 4 subjects had longer follow up due to the coronavirus infection of 2019 (COVID 19) and inability to schedule follow ups (approximately 6 to 8 months additional follow up for these subjects)", "eventGroups": [{"id": "EG000", "title": "Carvedilol", "description": "Approximately 70 subjects will be randomized to carvedilol\n\nCarvedilol: Carvedilol is a non selective beta blocker", "deathsNumAffected": 1, "deathsNumAtRisk": 21, "seriousNumAffected": 6, "seriousNumAtRisk": 21, "otherNumAffected": 14, "otherNumAtRisk": 21}, {"id": "EG001", "title": "Spironolactone", "description": "Approximately 70 subjects will be randomized to spironolactone\n\nSpironolactone: Spironolactone is an aldosterone antagonist and can lower blood pressure/ is used in heart failure", "deathsNumAffected": 0, "deathsNumAtRisk": 18, "seriousNumAffected": 5, "seriousNumAtRisk": 18, "otherNumAffected": 13, "otherNumAtRisk": 18}, {"id": "EG002", "title": "Usual Care", "description": "Approximately 70 subjects will be randomized to usual care/ standard care by primary care providers\n\nUsual care: standard care as per primary care provider", "deathsNumAffected": 1, "deathsNumAtRisk": 19, "seriousNumAffected": 3, "seriousNumAtRisk": 19, "otherNumAffected": 7, "otherNumAtRisk": 19}], "seriousEvents": [{"term": "Hospitalization for planned surgery", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Hospitalizations for planned surgery (hip, cataract, cancer, ablation)", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 21}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 19}]}, {"term": "Hospitalization for infection", "organSystem": "Infections and infestations", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "Infections including pneumonia, COVID, pyelonephritis", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 21}, {"groupId": "EG001", "numEvents": 3, "numAffected": 2, "numAtRisk": 18}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 19}]}, {"term": "Hospitalization for falls, accidents", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "Falls (mechanical, unclear etc)", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 21}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}]}, {"term": "Hospitalization for chest pain/ heart failure", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "ER visit/ hospitalization for chest pain/ hear failure", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 21}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}]}, {"term": "Hypotension, ER visit", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Low BP needing ER visit", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 21}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 18}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}]}, {"term": "Hospitalization for shortness of breath", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 21}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 19}]}], "otherEvents": [{"term": "Breast tenderness", "organSystem": "Endocrine disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 21}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 18}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}]}, {"term": "Renal dysfunction", "organSystem": "Renal and urinary disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 21}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 18}, {"groupId": "EG002", "numEvents": 2, "numAffected": 1, "numAtRisk": 19}]}, {"term": "abdominal discomfort", "organSystem": "Gastrointestinal disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 21}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}]}, {"term": "Dizziness/ Drowsiness/ Disequilibrium", "organSystem": "Cardiac disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 21}, {"groupId": "EG001", "numEvents": 4, "numAffected": 3, "numAtRisk": 18}, {"groupId": "EG002", "numEvents": 3, "numAffected": 2, "numAtRisk": 19}]}, {"term": "Musculoskeletal pain", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 21}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 18}, {"groupId": "EG002", "numEvents": 10, "numAffected": 6, "numAtRisk": 19}]}, {"term": "chest pain", "organSystem": "Cardiac disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 3, "numAtRisk": 21}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG002", "numEvents": 2, "numAffected": 1, "numAtRisk": 19}]}, {"term": "Fatigue", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 21}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}]}, {"term": "Falls", "organSystem": "Nervous system disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 21}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 19}]}, {"term": "Weight loss", "organSystem": "Endocrine disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 21}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 18}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 19}]}, {"term": "Atrial arrhythmia", "organSystem": "Cardiac disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 21}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 19}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": true}, "pointOfContact": {"title": "Vijay Nambi", "organization": "Michael E DeBakey Veterans Affairs Hospital", "email": "vijay.nambi@va.gov", "phone": "713-794-7300"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2022-04-22", "uploadDate": "2022-06-20T23:29", "filename": "Prot_SAP_000.pdf", "size": 204989}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-26"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "relevance": "LOW"}, {"id": "M10024", "name": "Hypertension", "relevance": "LOW"}, {"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC14", "name": "Heart and Blood Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000077261", "term": "Carvedilol"}, {"id": "D000013148", "term": "Spironolactone"}], "ancestors": [{"id": "D000000451", "term": "Mineralocorticoid Receptor Antagonists"}, {"id": "D000006727", "term": "Hormone Antagonists"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000062865", "term": "Diuretics, Potassium Sparing"}, {"id": "D000004232", "term": "Diuretics"}, {"id": "D000045283", "term": "Natriuretic Agents"}, {"id": "D000000319", "term": "Adrenergic beta-Antagonists"}, {"id": "D000018674", "term": "Adrenergic Antagonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000000975", "term": "Antioxidants"}, {"id": "D000020011", "term": "Protective Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000058668", "term": "Adrenergic alpha-1 Receptor Antagonists"}, {"id": "D000000317", "term": "Adrenergic alpha-Antagonists"}], "browseLeaves": [{"id": "M1718", "name": "Carvedilol", "asFound": "Depressive Disorder", "relevance": "HIGH"}, {"id": "M15943", "name": "Spironolactone", "asFound": "Flexible", "relevance": "HIGH"}, {"id": "M3671", "name": "Adrenergic beta-Antagonists", "relevance": "LOW"}, {"id": "M3797", "name": "Mineralocorticoid Receptor Antagonists", "relevance": "LOW"}, {"id": "M11871", "name": "Mineralocorticoids", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M7411", "name": "Diuretics", "relevance": "LOW"}, {"id": "M30025", "name": "Diuretics, Potassium Sparing", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M20755", "name": "Adrenergic Antagonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M4292", "name": "Antioxidants", "relevance": "LOW"}, {"id": "M21869", "name": "Protective Agents", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M29194", "name": "Adrenergic alpha-1 Receptor Antagonists", "relevance": "LOW"}, {"id": "M3669", "name": "Adrenergic alpha-Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "NaAg", "name": "Natriuretic Agents"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}]}}, "hasResults": true}